Extending the Life of Transplanted Kidneys

Episode Summary

Executive Summary: The episode explores Eladon Pharmaceuticals’ experimental immunosuppressant tegoprubart, aimed at replacing tacrolimus in transplantation to extend graft life and reduce toxicity. Steve Perrin argues CD40 ligand blockade could improve kidney transplant outcomes, reduce rejection, and potentially apply to islet cell transplant, xenotransplantation, and autoimmune/neurodegenerative disease.

Main Topics: The kidney transplant shortage and failed organ durability (Priority: 5/5): The discussion opens with the severe shortage of donor kidneys and the problem that transplanted kidneys often last only 10-15 years, forcing patients back onto dialysis and waiting lists. Limits of current immunosuppression (Priority: 5/5): Perrin explains that tacrolimus and standard polypharmacy reduced acute rejection but caused long-term kidney damage and systemic toxicities, leaving the field focused on a better balance between efficacy and safety. CD40 ligand as a new mechanistic target (Priority: 5/5): Eladon’s strategy centers on blocking CD40 ligand to more selectively interrupt T-cell/B-cell signaling, potentially inducing tolerance rather than broadly suppressing immunity. Tegoprubart clinical and preclinical results (Priority: 5/5): The interview highlights Phase 1B kidney transplant data, non-human primate liver data, and early islet-cell transplant findings suggesting improved kidney function, graft survival, and tolerability. Broader transplant and disease applications (Priority: 4/5): Perrin describes possible uses beyond kidney transplantation, including heart, lung, islet cells, xenotransplantation, and possibly ALS and other autoimmune/neuroinflammatory diseases. Development strategy and capital runway (Priority: 3/5): Eladon is running multiple trials in parallel and expects current cash to last into late 2026, with key readouts planned from the Phase II Bestow study and the University of Chicago islet-cell trial.

Key Arguments: Kidney transplantation is lifesaving, but the organ shortage remains severe, with roughly 100,000 patients on the waiting list and about 5,000 deaths annually in the U.S. Even successful kidney transplants are often temporary because grafts commonly fail after 10-15 years, leading to repeat transplants and years of costly dialysis. Tacrolimus improved short-term rejection outcomes but has chronic nephrotoxicity and other adverse effects, including hypertension, diabetes, and neurologic symptoms. A more targeted CD40 ligand inhibitor could better preserve graft function while reducing systemic immunosuppression-related toxicity. Tegoprubart may promote immune tolerization by shifting immune responses toward regulatory T cells rather than simply suppressing white blood cells broadly. Early clinical data suggest better kidney function with tegoprubart than with standard tacrolimus-based regimens, and preclinical primate studies support durability and tolerance. The platform may have value well beyond kidney transplantation, including xenotransplantation and autoimmune or neurodegenerative disease research.

Data Points: Kidney transplant waiting list: about 100,000 people - U.S. patients waiting for a kidney transplant Annual deaths on kidney transplant list: approximately 5,000 per year - U.S. patients dying while waiting for a transplant Dialysis cost per patient: about $100,000 per year - Cost while waiting for another kidney transplant Dialysis survival: about 5 years - Average survival on dialysis cited in the interview Typical transplanted kidney function duration: 10 to 15 years - Common long-term survival for transplanted kidneys Tacrolimus acute rejection in early trials: about 30% - Initial tacrolimus trials, later improved with optimization and combination therapy Current acute rejection rates: high single digits - Modern standard of care with optimized tacrolimus-based regimens Diabetes risk from tacrolimus: up to 30% - Patients on tacrolimus may develop diabetes due to beta-cell toxicity Mean eGFR on tegoprubart: 68 - Phase 1B kidney transplant data at one year in patients remaining on tegoprubart Mean eGFR on standard of care: 53 - Comparison kidney function under tacrolimus-based standard care Non-human primate median survival: 587 days - Liver allotransplant study with tegoprubart as part of immunosuppression Primate long-term off-treatment survival: 25% survived long after withdrawal - Subset of primates remained alive after stopping drug Longest off-treatment survival animal: more than 2 years - One primate survived more than two years after treatment withdrawal Patient duration after pig kidney transplant: past 7 months - First human pig kidney transplant recipient mentioned Cash runway: to the end of 2026 - Eladon’s projected funding horizon Bestow study timing: top-line data in November - Phase II head-to-head kidney transplant trial readout University of Chicago islet trial timing: interim data by end of year - Investigator-led type 1 diabetes/islet-cell transplant study

Pivotal Quotes: "the new bogey of the Holy Grail would be one transplant for life" — Steve Perrin: Describing the field’s ultimate goal for transplant durability "Tegoprobart is designed to block CD40 ligand, a co-stimulatory pathway or molecule" — Steve Perrin: Explaining the drug’s mechanism of action "The same drug that is trying to protect the organ from rejection actually causes chronic long-term damage" — Steve Perrin: Discussing tacrolimus nephrotoxicity and the need for an alternative

Implications: If tegoprubart succeeds, transplant care could shift from broad immune suppression to targeted tolerance-building, improving graft longevity, reducing side effects, and potentially expanding access through better use of scarce organs and xenotransplantation.